Four Tiny but Potent Mutual Funds
Let's get really contrarian.
Let's get really contrarian.
Let's get really contrarian and take a look at some of the smallest funds in the Morningstar 500. They're being ignored by fund investors, but they've really got a lot to like.
Queens Road Small Cap Value (QRSVX)
Manager Steve Scruggs has done a great job of deep value investing at this fund, as its 4-star Morningstar Rating indicates. He's produced great results since the fund was launched in 2002. Its return on $10,000 since that time is $25,500 versus $20,100 for the average small-value fund. Yet, with an asset base of just $57 million, the fund has plenty of flexibility to buy the neglected small-cap names it covets.
Scruggs looks for companies dominating their niche, such as publisher Scholastic (SCHL), and throwing off a lot of cash. Interestingly, that has led him to a sizable tech weighting--27% of stocks--and a light financials weighting (10% of stocks). However, Scruggs is buying cheaper, more-mundane tech stocks than those such as Google (GOOG). He owns Tech Data , a big distributor of hardware and software to information technology departments, and Hurco (HURC), which makes software and systems for metal cutting.
Ariel Focus (ARFFX)
This mutual fund was launched in 2005 and it is still just a $51 million fund, but it's no dog. Charles Bobrinskoy and Tim Fidler apply Ariel's approach to large caps. As the name makes clear, they are keeping the fund in a concentrated basket of 24 stocks. Can Ariel's emphasis on stable, low-valuation companies work in a focused large-cap fund? I think so. The emphasis on stability has kept volatility roughly in line with other large-blend funds despite the concentration. Moreover, large-cap stocks appear to be relatively cheap these days, so it's a strategy that should work well. Interestingly, the portfolio of fiscally strong but cheap stocks held up much better than did Ariel (ARGFX) and Ariel Appreciation (CAAPX) in 2008, yet they still enjoyed strong performances in 2009, as well. Today, the portfolio is top-heavy with dependable blue-chip names such as ExxonMobil (XOM), IBM (IBM), Zimmer (ZMH), and Walgreen (WAG).
Masters Select Focused Opportunities
Now, this fund really counts as contrarian. It has a Morningstar rating of 1 star, and its 20-stock portfolio has added up to high risk even though its picks come from three different firms plying three very different strategies. That diversity of strategies is supposed to tone down the volatility of a focused portfolio, but the three firms have collectively leaned heavily toward financials and energy, two of the market's more volatile sectors.
If you're still reading, here's why this fund is a pretty good bet: Chris Davis and Ken Feinberg are excellent managers who just went through their worst three-year stretch on record. That's not likely to happen again. I also like Mutual Series' Philippe Brugere-Trelat and Peter Langerman. They're seasoned investors who bring a welcome note of conservatism to the fund. Finally, the third sleeve is run by Frank Sands Jr. and Michael Sramek of Sands Capital. The pair runs a low-turnover high-growth strategy that has had a headwind for most of the past 10 years. That's not likely to continue, and this fund could well have a bright future. My only gripe is that the expense ratio is on the high side, but it can come down with asset growth.
WHG Balanced
This fund has a mere $11 million in assets and a 2-star rating, so it's understandable that people would pass it over, but there's more there than meets the eye.
The fund has been around since 2006, but a virtual clone, GAMCO Westwood Balanced (WEBAX), dates back to 1991, and Mark Freeman and Susan Byrne have a strong record over that period. Moreover, it's conservatively positioned with high-quality stocks and high-quality bonds. That's meant the fund lagged its peers in recent years, but it could be set to pop when the market's seemingly insatiable appetite for risk vanishes.
This article originally appeared in Morningstar FundInvestor.
FundInvestor Newsletter | ||||
Morningstar FundInvestor is a 48-page newsletter dedicated to helping investors pick great mutual funds, build winning portfolios, and monitor their funds for | greater gains. This one-year subscription consists of 12 monthly issues, a Reader's Guide, and four free investing reports. Learn more. | |||
$129.00 for 12 Print Issues | $119.00 for 12 PDF Issues | |||
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.